Cantor Fitzgerald Reiterates Overweight on Y-mAbs Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and maintained a $20 price target.
September 09, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Y-mAbs Therapeutics, maintaining a $20 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a $20 price target by a reputable analyst suggests positive sentiment and potential upside for YMAB, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100